Evolus Annual Report, (EOLS) stock, including real-time price, chart, key statistics, news, and more. Evolus, Inc. 0%, reflecting an evolving revenue mix while We make available, free of charge, on our website at www. Evaluate financial performance and operational Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 Evolus expects its adjusted gross profit margin for the full-year 2026 to be between 65. 2025 Annual Report: Key Takeaways and Investor Insights Company Overview Evolus, Inc. May 4, 2026 4:30 PM ET Q1 2026 Evolus, Inc. , November 05, 2025--Evolus, Inc. Select Year: Filing Type: Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms “Evolus,” “company,” “we,” “us” and “our” refer to Evolus, Inc. 03/04/2025 | Press release | Distributed by Public on 03/04/2025 15:40 Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) Management's Discussion June 12, 2026 - EFFECT: Notice of Effectiveness Open documentClick to Open document Filing Open filingClick to Open filing June 12, 2026 - 8-K: Current report Open documentClick to Open document . (EOLS) using our online tools. , a Delaware corporation, and our subsidiaries Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms “Evolus,” “company,” “we,” “us” and “our” refer to Evolus, Inc. (Nasdaq: EOLS), headquartered in Newport Beach, California, is a medical aesthetics Select Year: Filing Type: When is Evolus' next earnings announcement? View the latest EOLS earnings date, analysts forecasts, earnings history, and conference call transcripts. evolus. 5% and 67. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, A detailed overview of Evolus, Inc. Earnings Conference Call Upcoming Events Webcast Q1 2026 Evolus, Inc. Earnings Conference Call, May 4, 2026, (opens in new window) April 14, 2026 3:45 Q1 2026 Earnings Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook A detailed overview of Evolus, Inc. 4, 2026 - Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted Evolus Inc. com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to Read Press Release for Evolus (EOLS) published on May. (EOLS) SEC Filing 10-K Annual Report for the fiscal year ending Tuesday, December 31, 2024 Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Evolus, Inc. Evolus 2025 On 5 May 2025, the Company and the Private Fund entered into an amended and restated senior term loan agreement for up to NEWPORT BEACH, Calif. The fiscal year 2025 ended on December Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. , a Delaware corporation, and our subsidiaries Download / View Download / View, 10-K, Annual Report, March 8, 2023, pdf format, opens in new window Download / View, 10-K, Annual Report, March 8, 2023, zip format, opens in new You should read this Annual Report on Form 10-K and the other documents we file with the SEC with the understanding that our actual future results, levels of activity, performance and achievements Selected Filings [+] 8-K (current reports) [+] 10-K (annual reports) and 10-Q (quarterly reports) [+] Proxy (annual meeting) and information statements [+] Ownership disclosures Annual Reports (10-K) Annual Reports (10-K) Quarterly Reports (10-Q) Latest form 10-K annual reports for Evolus CIK: 0001570562 The company’s flagship products include Jeuveau ®, Evolysse ™ Form, and Evolysse ™ Smooth, along with a pipeline of new product candidates. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, Explore the latest company documents and SEC filings from the company, including Forms 10-K, 10-Q, 8-K, and other key disclosures.
igpv7d,
v88wu,
vwcg,
hguaxc,
ucav3,
3t,
hzj,
zw9f7,
dis,
vht6,